ClinicalTrials.gg
Not yet recruitingNCT07845188Updated Sep 28, 2026

Nutritional Status of Gaucher Disease Patients

An observational study in Gaucher Disease, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Assiut University · Observational

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
84
Ages
1 Month and older
Sex
All
01

Study summary

This cross-sectional study aims to evaluate the nutritional status of patients with Gaucher disease attending Assiut University Children's Hospital using anthropometric measurements and body composition analysis.

Read the detailed description

Gaucher disease is a lysosomal storage disorder that may affect growth and nutritional status, particularly in children. This observational study will include patients with confirmed Gaucher disease (types 1, 2, and 3) who attend follow-up visits at Assiut University Children's Hospital.

Nutritional status will be assessed by detailed dietary history, anthropometric measurements (weight, height, BMI, mid-arm circumference), and body composition analysis using bioelectrical impedance analysis (BIA).

02

Conditions studied

  • Gaucher Disease

Browse trials for

Keywords

  • Gaucher disease
  • Nutritional status
  • Body composition
  • Anthropometry
  • Assiut
03

In context

Gaucher Disease

177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.

This study's planned enrollment of 84 is above the median of 63 across 67 observational studies indexed under Gaucher Disease.

Browse Gaucher Disease studies →

Lead sponsor

Assiut University is the lead sponsor of 5,088 studies on the registry; 2,185 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with confirmed Gaucher disease attending Assiut University Children's Hospital for follow-up visits.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of Gaucher disease (type 1, 2, or 3)
  • Undergoing a follow-up visit at Assiut University Children's Hospital
  • Written from caregivers

Exclusion criteria

Exclusion Criteria:

  • Other autosomal recessive lysosomal storage diseases
  • Not undergoing a follow-up visit at Assiut University Children's Hospital
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
84 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single cohort: Gaucher Disease Patients

    Patients with confirmed Gaucher disease (types 1, 2, and 3) who will undergo nutritional assessment including anthropometry and body composition analysis.

06

What researchers measure

Primary outcomes

  1. Prevalence of underweight

    Proportion of patients with weight-for-age below -2 standard deviations according to WHO growth charts.

    Time frame: Baseline

Secondary outcomes

  1. Prevalence of stunting

    Proportion of patients with height-for-age below -2 standard deviations according to WHO growth charts.

    Time frame: Baseline

  2. Mean body mass index

    Mean body mass index (BMI) in kg/m².

    Time frame: Baseline

  3. Mean mid-arm circumference

    Mean mid-upper arm circumference in centimeters.

    Time frame: Baseline

  4. Mean fat mass percentage

    Mean fat mass percentage measured by bioelectrical impedance analysis (BIA).

    Time frame: Baseline

  5. Mean lean body mass

    Mean lean body mass measured by bioelectrical impedance analysis (BIA).

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartEst.
Sep 26, 2026
Primary completionEst.
Sep 26, 2027
CompletionEst.
Feb 25, 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845188
Lead sponsor
Assiut University
Responsible party
Salma Hassanein Salem Ahmed (Resident Physician, Department of Pediatrics, Assiut University) — Principal investigator
First posted
Sep 28, 2026
Start date
Sep 26, 2026 (estimated)
Primary completion
Sep 26, 2027 (estimated)
Completion
Feb 25, 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Salma H Salem, Resident
Contact
Salma.17308823@med.aun.edu.eg
+20 10 14620228
Mostafa M Embaby, prof
study chair · Pediatrics Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion